Education
About Us
Working with TipRanks
Follow Us
Harvard Apparatus Regenerative Technology (HRGN)
OTHER OTC:HRGN
HRGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.94 - $5.90
Previous CloseN/A
Volume1.21K
Average Volume (3M)1.91K
Market Cap
$32.96M
Enterprise Value$26.59M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.18
Next Earnings
May 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding17,168,980
10 Day Avg. Volume1,792
30 Day Avg. Volume1,912
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Harvard Apparatus Regenerative Technology News
HRGN FAQ
What was Harvard Apparatus Regenerative Technology’s price range in the past 12 months?
Harvard Apparatus Regenerative Technology lowest stock price was $0.94 and its highest was $5.90 in the past 12 months.
What is Harvard Apparatus Regenerative Technology’s market cap?
Harvard Apparatus Regenerative Technology’s market cap is $32.96M.
When is Harvard Apparatus Regenerative Technology’s upcoming earnings report date?
Harvard Apparatus Regenerative Technology’s upcoming earnings report date is May 19, 2025 which is 130 days ago.
How were Harvard Apparatus Regenerative Technology’s earnings last quarter?
Harvard Apparatus Regenerative Technology released its earnings results on May 19, 2025. The company reported -$0.104 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.104.
Is Harvard Apparatus Regenerative Technology overvalued?
According to Wall Street analysts Harvard Apparatus Regenerative Technology’s price is currently Overvalued.
Does Harvard Apparatus Regenerative Technology pay dividends?
Harvard Apparatus Regenerative Technology does not currently pay dividends.
What is Harvard Apparatus Regenerative Technology’s EPS estimate?
Harvard Apparatus Regenerative Technology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Harvard Apparatus Regenerative Technology have?
Harvard Apparatus Regenerative Technology has 17,168,980 shares outstanding.
What happened to Harvard Apparatus Regenerative Technology’s price movement after its last earnings report?
Harvard Apparatus Regenerative Technology reported an EPS of -$0.104 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.564%.
Which hedge fund is a major shareholder of Harvard Apparatus Regenerative Technology?
Currently, no hedge funds are holding shares in HRGN
Company Description
Harvard Apparatus Regenerative Technology
Biostage, Inc. is a biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. It operates through Cellframe technology, engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. The company was founded on May 3, 2012 and is headquartered in Holliston, MA.
Technical Analysis
Lisata Therapeutics
―
Moleculin Biotech
―
Pulmatrix
―
SAB Biotherapeutics
―
Longeveron
―
Ownership Overview
Options Prices
Currently, No data available
---